{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:09:37Z","timestamp":1788887377236,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Cabazitaxel is an established treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC), but outcomes beyond the conventional 10-cycle threshold remain incompletely characterized. This threshold largely reflects clinical trial design. We therefore evaluated outcomes associated with cabazitaxel treatment beyond 10 cycles using a predefined 8-month landmark analysis intended to reduce early immortal time bias. Methods: This retrospective single-center study included 98 patients with mCRPC treated with cabazitaxel between 2010 and 2020. The final cohort comprised 74 patients who were alive at the predefined 8-month landmark. The primary endpoint was overall survival (OS) from the landmark, and secondary endpoints included conditional radiologic progression-free survival (rPFS), conditional prostate-specific antigen progression-free survival (PSA-PFS), treatment response, and safety. Results: Among the 74 patients included in the landmark cohort, 45 (60.8%) ultimately received \u226410 cycles and 29 (39.2%) received &gt;10 cycles. The median landmark OS was numerically longer in the &gt;10-cycle group (17.6 vs. 10.4 months; p = 0.123). Conditional rPFS and PSA-PFS did not differ significantly between groups (&gt;10 vs. \u226410 cycles: 4.4 vs. 2.3 months; p = 0.255 and 4.2 vs. 2.2 months; p = 0.137, respectively). In a broader baseline-adjusted sensitivity model, the treatment duration association was not statistically significant (HR for \u226410 vs. &gt;10 cycles, 1.58; 95% CI, 0.91\u20132.74; p = 0.105). The crude cumulative proportions of grade \u22653 neutropenia and febrile neutropenia were higher in the &gt;10-cycle group. Conclusions: Cabazitaxel treatment beyond 10 cycles appeared feasible in selected patients. However, future-derived exposure classification and responder enrichment limit causal interpretation. The survival association was not consistently maintained across sensitivity analyses, supporting a hypothesis-generating interpretation rather than evidence of a survival benefit from continuation beyond 10 cycles.<\/jats:p>","DOI":"10.3390\/jcm15186966","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:46:04Z","timestamp":1788885964000},"page":"6966","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-7741","authenticated-orcid":false,"given":"Hakan","family":"Taban","sequence":"first","affiliation":[{"name":"Medical Oncology Clinic, Medical Park Ankara Hospital, Ankara 06680, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-1049","authenticated-orcid":false,"given":"Sercan","family":"Aksoy","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-3980","authenticated-orcid":false,"given":"Yasemin","family":"Evlendi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-4895","authenticated-orcid":false,"given":"Burak Yasin","family":"Akta\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-6921","authenticated-orcid":false,"given":"Ferit","family":"Aslan","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Medical Park Ankara Hospital, Ankara 06680, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-4669","authenticated-orcid":false,"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[{"name":"Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"European Association of Urology (2026, June 22). EAU Guidelines on Prostate Cancer. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2026_2026-03-14-104356_ixav.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(25)02221-4","article-title":"Prostate cancer","volume":"407","author":"Fonteyne","year":"2026","journal-title":"Lancet"},{"key":"ref_4","unstructured":"National Comprehensive Cancer Network (2026, June 18). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 5. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2026.01.015","article-title":"Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"Sternberg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"117","article-title":"Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer","volume":"5","author":"Paller","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg\/m2) and the Currently Approved Dose (25 mg\/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer\u2014PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.18632\/oncotarget.27031","article-title":"Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: A final, pooled analysis of the compassionate use programme and early access programme","volume":"10","author":"Malik","year":"2019","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.14509","article-title":"An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel CAPRISTANA","volume":"123","author":"Carles","year":"2019","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update","volume":"43","author":"Garje","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/ejhpharm-2019-001955","article-title":"Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: Is there a benefit?","volume":"28","author":"Arasaratnam","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.21873\/anticanres.13612","article-title":"Therapeutic outcome of >10 cycles of cabazitaxel for castration-resistant prostate cancer: A multi-institutional study","volume":"39","author":"Shiota","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0019-509X.146721","article-title":"Beyond ten cycles of cabazitaxel for castrate-resistant prostate cancer","volume":"51","author":"Noronha","year":"2014","journal-title":"Indian J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Malik, Z., Di Lorenzo, G., Pichler, A., De Giorgi, U., Hitier, S., Ecstein-Fraisse, E., Ozatilgan, A., and Carles, J. (2020). Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use\/Expanded Access Programs and CAPRISTANA Registry. Cancers, 12.","DOI":"10.3390\/cancers12040995"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available","volume":"183","author":"Robins","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Spetsieris, N., Boukovala, M., Patsakis, G., Alafis, I., and Efstathiou, E. (2020). Neuroendocrine and aggressive-variant prostate cancer. Cancers, 12.","DOI":"10.3390\/cancers12123792"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6966\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:49:17Z","timestamp":1788886157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/6966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":24,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15186966"],"URL":"https:\/\/doi.org\/10.3390\/jcm15186966","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}